Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-2

Pralmorelin, Growth Hormone Releasing Peptide-2, KP-102

Quick Stats
Studies 230
Trials 1
Score 4
2009 pubmed 11 citations

Determinants of GH-releasing hormone and GH-releasing peptide synergy in men.

Veldhuis. Johannes D JD; Bowers. Cyril Y CY

Key Findings

  • GHRH‑GHRP‑2 synergy drops sharply with increasing age and abdominal‑visceral fat
  • Higher IGF‑I and IGFBP‑3 levels predict stronger GH response to the peptide combo
  • Basal GH secretion is positively linked to testosterone and estradiol levels

Practical Outcomes

  • For biohackers, pairing GHRP‑2 with a GHRH analog (e.g., CJC‑1295) can give a bigger GH surge, but the effect will be blunted if you’re older or carry excess visceral fat. Reducing belly fat and supporting IGF‑1 (through nutrition, sleep, and training) may enhance the response. Monitoring and, if needed, optimizing testosterone/estradiol levels could also improve baseline GH output.

Summary

The study shows that the ability of GHRP-2 (a growth‑hormone‑releasing peptide) to boost GH when paired with a GHRH drug depends on age, belly fat, and IGF‑1 levels. Older men and those with more visceral fat get less GH boost, while higher IGF‑1 and IGFBP‑3 improve it. Basal (non‑pulsatile) GH also rises with higher testosterone and estradiol.

Abstract

Age, sex steroids, and abdominal-visceral fat (AVF) jointly affect pulsatile growth hormone (GH) secretion. Pulsatile GH secretion in turn is controlled by GH-releasing hormone (GHRH), GH-releasing peptide (GHRP), and somatostatin. Marked stimulation of pulsatile GH secretion is achieved via GHRH-GHRP synergy. Nonetheless, how key modulators of GH secretion, such as age, sex steroids, and body mass index, modify GHRH-GHRP synergy is not known. The present strategy was to 1) infuse GHRH and GHRP-2 simultaneously to evoke synergy and 2) downregulate the gonadal axis with leuprolide and then restore placebo (Pl) or testosterone (T) to clamp the sex steroid milieu. Forty-seven men [18-74 yr of age, T = 7-1,950 ng/dl, estradiol (E(2)) = 5-79 pg/ml, insulin-like growth factor (IGF)-I = 115-817 microg/l, AVF = 11-349 cm(2)] were studied. GHRH-GHRP synergy correlated negatively with age and AVF (both P < 0.001) and positively with IGF-I (P < 0.001) and IGF-binding protein (IGFBP)-3 (P = 0.031). Unstimulated basal (nonpulsatile) GH secretion correlated positively with T (P = 0.015) and E(2) (P = 0.004) concentrations. Fasting pulsatile GH secretion varied negatively with age (P = 0.017) and positively with IGF-I (P = 0.002) and IGFBP-3 (P = 0.001). By stepwise forward-selection multivariate analyses, AVF, IGF-I, and IGFBP-3 together explained 60% of the variability in GHRH-GHRP synergy (P < 0.001), E(2) accounted for 17% of the variability in basal GH secretion (P = 0.007), and IGF-I explained 20% of the variability in fasting pulsatile GH secretion (P = 0.002). In conclusion, a paradigm examining GHRH-GHRP synergy under a sex steroid clamp reveals highly selective control of basal, pulsatile, and synergistic peptide-driven GH secretion by AVF, E(2), and IGF-I in healthy men.

Study Information

Provider

pubmed

Year

2009

Date

2009-02-24T00:00:00.000Z

DOI

10.1152/ajpendo.91001.2008

Citations

11

References

44